NervGen is a clinical-stage biopharmaceutical company with no approved products or revenue, focused entirely on developing NVG-291, a drug candidate for spinal cord injury (SCI). After SCI, the body upregulates inhibitory molecules (CSPGs) that block the nervous system from repairing itself. NVG-291 is a synthetic peptide that blocks the receptor (PTPσ) CSPGs use to suppress repair, and in preclinical and early clinical testing has promoted nerve regeneration and functional recovery. It is administered as a once-daily subcutaneous injection. NervGen's lead program targets chronic and subacute SCI — a condition affecting roughly 312,000 Americans with no approved pharmacologic therapies that restore function. In June 2025, NervGen reported positive topline data from the chronic cohort of its Phase 1b/2a CONNECT SCI Study, and is now planning a Phase 3 trial in chronic SCI. Preclinical data also suggests NVG-291 may be applicable in stroke, MS, ALS, and other neurological conditions sharing the same CSPG/PTPσ mechanism, though none have entered clinical trials. NervGen also has NVG-300, a next-generation preclinical candidate for ischemic stroke and SCI. NervGen's technology is exclusively licensed from Case Western Reserve University. The company funds operations through equity financings and non-dilutive grants, runs a lean eight-person team, and outsources clinical and manufacturing work to CROs and CMOs. Commercialization would come through independent launch or a partnership with a larger pharma company, contingent on Phase 3 success and regulatory approval.